Investigating the Targeting Power to Brain Tissues of Intranasal Rasagiline Mesylate-Loaded Transferosomal In Situ Gel for Efficient Treatment of Parkinson’s Disease

Rasagiline mesylate (RSM) is a hydrophilic drug with poor oral bioavailability (36%) because of hepatic first-pass metabolism. The present study focuses on delivering RSM directly to the brain through its inclusion within transferosomal in situ gel administered through the intranasal (IN) route. Tra...

Descripción completa

Detalles Bibliográficos
Autores principales: ElShagea, Hala N., Makar, Rana R., Salama, Alaa H., Elkasabgy, Nermeen A., Basalious, Emad B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9967009/
https://www.ncbi.nlm.nih.gov/pubmed/36839855
http://dx.doi.org/10.3390/pharmaceutics15020533

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9967009/
https://www.ncbi.nlm.nih.gov/pubmed/36839855
http://dx.doi.org/10.3390/pharmaceutics15020533

Ejemplares similares